Some policy reforms can help incentivize more use of value-based contracts, but overall an area that needs more work is value-based contracts with pharmaceutical companies, said Steven Peskin, MD, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Some policy reforms can help incentivize more use of value-based contracts, but overall an area that needs more work is value-based contracts with pharmaceutical companies, said Steven Peskin, MD, executive director, director of population health, Horizon Blue Cross Blue Shield of New Jersey.
Transcript
What policy reforms are needed in order to successfully incentivize the use of value-based contracts?
There are policy reforms related to that recognition that self-referral and the so-called Stark amendment may not be in the best interest of or it has a negative impact on value-based arrangements. So, that that would certainly be one.
I would say another would be that with commercial payers oftentimes, at least to some extent taking some license or following or acknowledging the important role of the Centers for Medicare and Medicaid Services and Center for Medicare and Medicaid Innovation. So, the OCM [Oncology Care Model] as well intentioned as it was didn't end up working very well. And it just doesn't apply to cancer care other areas, as well. So that kind of thought leadership and framing at the federal level that allows some of the private payers, commercial payers like ours to work within a particular policy framework. So, there's a couple of things that come to mind,
How have value-based contracts with pharmaceutical companies progressed?
The number of value-based contracts that exist between pharmaceutical/life sciences companies, biopharmaceuticals, cell therapy, gene therapy, is really few and far between. And it really is an area that needs to evolve. It’s something that is sort of a societal expectation, the way in which we as a nation approach health care and percentage of the gross domestic product. So, it’s definitely a work in progress and it needs a lot of work.
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Shaping Dermatology's Future by Increasing Access, Data, and Advocacy
March 7th 2025Thy N. Huynh, MD, FAAD, Bruce A. Brod, MHCI, MD, FAAD, and Melissa Piliang, MD, FAAD, discussed expanding access to pediatric dermatology, dermatology data aggregation, and advocacy for Medicare physician payment reform, respectively.
Read More